RET and cholangiocarcinoma: Between August 22, 2016, and November 19, 2021, 344 patients were centrally screened for FGFR-activating mutations/rearrangement (urothelial cancer, esophageal cancer, NSCLC, and cholangiocarcinoma) or RET-activating mutations/translocations (NSCLC); 35 were enrolled across three sites in China, three sites in South Korea, and four sites in Taiwan (Supplementary Figure S1).